LINC01106: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: LINC01106

NCBI ID: G151009

LINC01106

Other Name(s): FLJ38359 | DKFZp686K04236 | long intergenic non-protein coding RNA 1106 | Long intergenic non-protein coding RNA 1106

LINC01106: A Potential Drug Target for Cancer and Neurodegenerative Diseases

LINC01106 is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a member of the LINC subfamily of RNA-binding proteins, which are known for their ability to interact with RNA molecules. LINC01106 has been shown to play a role in the regulation of gene expression, and is potential drug target in the treatment of various diseases.

The LINC01106 protein is composed of 1,212 amino acids and has a calculated molecular mass of 18.1 kDa. It is expressed in a variety of tissues, including the brain, heart, and liver, and has been shown to localize to specific cellular compartments in these organisms. LINC01106 is also known to be a good candidate biomarker for certain diseases, such as cancer and neurodegenerative diseases.

One of the key functions of LINC01106 is its ability to interact with RNA molecules. This interaction allows LINC01106 to regulate the expression of other genes, and is a potential drug target in itself. LINC01106 has been shown to interact with a variety of RNA molecules, including microRNAs and large RNA molecules. These interactions are regulated by a variety of factors, including the activity of enzymes that modify the structure of LINC01106.

In addition to its role in gene regulation, LINC01106 has also been shown to play a role in the regulation of cellular processes. For example, LINC01106 has been shown to be involved in the regulation of cell adhesion, a process that is important for the maintenance of tissue structure and function. LINC01106 has also been shown to be involved in the regulation of cell signaling pathways, which are important for the regulation of cellular processes such as metabolism and growth.

Given its role in gene regulation and cellular processes, LINC01106 is a potential drug target in the treatment of various diseases. For example, LINC01106 has been shown to be involved in the regulation of cancer cell growth, and may be a useful target for cancer therapies. LINC01106 has also been shown to be involved in the regulation of neurodegenerative diseases, and may be a useful target for these therapies as well.

In conclusion, LINC01106 is a protein that has been shown to play a role in the regulation of gene expression and cellular processes. It is a potential drug target in the treatment of various diseases, including cancer and neurodegenerative diseases. Further research is needed to fully understand the role of LINC01106 in these processes, and to develop effective therapies based on this protein.

Protein Name: Long Intergenic Non-protein Coding RNA 1106

The "LINC01106 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01106 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets